|
1) Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complica-tions of iron overload in patients with thalassemia major. N Engl J Med. 1994; 331: 567-73
|
|
|
|
2) Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007; 78: 487-94
|
|
|
|
|
|
3) Fox F, Kundgen A, Nachtkamp K, et al. Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only. Blood. 2009; 114: abst 1747
|
|
|
|
|
|
4) Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients？ A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res. 2010; 34: 864-70
|
|
|
|
|
|
5) Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007; 109: 4586-8
|
|
|
|
|
|
6) Altes A, Remacha AF, Sarda P, et al. Early clinical impact of iron overload in stem cell transplantation. A prospective study. Ann Hematol. 2007; 86: 443-7
|
|
|
|
|
|
7) Altes A, Remacha AF, Sarda P, et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant. 2004; 34: 505-9
|
|
|
|
|
|
8) Evens AM, Mehta J, Gordon LI. Rust and corrosion in hematopoietic stem cell trans-plantation: the problem of iron and oxidative stress. Bone Marrow Transplant. 2004; 34: 561-71
|
|
|
|
|
|
9) Miceli MH, Dong L, Grazziutti ML, et al. Iron overload is a major risk factor for severe infection after autologous stem cell trans-plantation: a study of 367 myeloma patients. Bone Marrow Transplant. 2006; 37: 857-64
|
|
|
|
|
|
10) Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008; 83: 858-61
|
|
|
|
|
|
11) Badawi MA, Vickars LM, Chase JM, et al. Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome. Adv Hematol. 2010; 2010: 164045
|
|
|
|
|
|
12) Breccia M, Loglisci G, Salaroli A, et al. Deferasirox treatment interruption in a trans-fusion-requiring myelodysplastic patient led to loss of erythroid response. Acta Haematol. 2010; 124: 46-8
|
|
|
|
|
|
13) Capalbo S, Spinosa G, Franzese MG, et al. Early deferasirox treatment in a patient with myelo-dysplastic syndrome results in a long-term reduction in transfusion requirements. Acta Haematol. 2009; 121: 19-20
|
|
|
|
|
|
14) Di Tucci AA, Murru R, Alberti D, et al. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol. 2007; 78: 540-2
|
|
|
|
|
|
15) Gattermann N, Finelli C, Porta M, et al. Hematologic responses in myelodysplastic syndromes (MDS) patients treated with deferasirox: an EPIC post-hoc analysis using International Working Group (IWG) 2006 criteria. Blood. 2010; 116: 1199 (Abst. #2912)
|
|
|
|
|
|
16) Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996; 94: 288-99
|
|
|
|
|
|
17) Jensen PD, Jensen IM, Ellegaard J. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol. 1992; 80: 121-4
|
|
|
|
|
|
18) Koh KN, Park M, Kim BE, et al. Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia. J Pediatr Hematol Oncol. 2010; 32: 611-4
|
|
|
|
|
|
19) Messa E, Cilloni D, Messa F, et al. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 2008; 120: 70-4
|
|
|
|
|
|
20) Molteni A, Riva M, Speziale V, et al. Iron-chelation therapy in MDS / IMF patients: Does it really impact on transfusion requirement？ Haematologica. 2010; 95: 566 (Abst. #1410)
|
|
|
|
|
|
21) Nishiuchi T, Okutani Y, Fujita T, et al. Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome. Intl J Hematol. 2010; 91: 333-5
|
|
|
|
|
|
22) Okabe H, Suzuki T, Omori T, et al. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelo-dysplastic syndrome. Rinsho ketsueki. 2009; 50: 1626-9
|
|
|
|
|
23) Oliva EN, Ronco F, Marino A, et al. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion. 2010; 50: 1568-70
|
|
|
|
|
|
24) Park SJ, Han CW. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci. 2008; 23: 320-3
|
|
|
|
|
|
25) Smeets ME, Vreugdenhil G, Holdrinet RS. Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol. 1996; 51: 243-4
|
|
|
|
|
|
26) Vreugdenhil G, Swaak AJ, Kontoghiorghes GJ, et al. Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients. Lancet. 1989; 2: 1398-9
|
|
|
|
|
|
27) Weintraub LR, Conrad ME, Crosby WH. Iron-loading anemia. Treatment with repeated phlebotomies and pyridoxine. N Engl J Med. 1966; 275: 169-76
|
|
|
|
|
|
28) Gattermann N, Finelli C, Porta M, et al. Factors associated with hematologic responses in myelodysplastic syndromes (MDS) patients treated with deferasirox: an EPIC post-hoc analysis using international working group (IWG) 2006 criteria. Haematologica. 2011; 96(S2): 111 (Abst. #0269)
|
|
|
|
|
|
29) Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006; 91: 1588-90
|
|
|
|
|
|
30) Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005; 23: 7594-603
|
|
|
|
|
|
31) Ito K, Hirao A, Arai F, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature. 2004; 431: 997-1002
|
|
|
|
|
|
32) Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood. 1993; 82: 3610-5
|
|
|
|
|
|
33) Kling PJ, Dragsten PR, Roberts RA, et al. Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy. Br J Haematol. 1996; 95: 241-8
|
|
|
|
|
|
34) Dezza L, Cazzola M, Danova M, et al. Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U. K. 1989; 3: 104-7
|
|
|
|
|
|
35) Haq RU, Wereley JP, Chitambar CR. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp Hematol. 1995; 23: 428-32
|
|
|
|
|
|
36) Messa E, Carturan S, Maffe C, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelo-dysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010; 95: 1308-16
|
|
|
|
|